CIT-013

N/A

Report date: 2026/03/31 20:00:21
First In Class

Base Information

Drug NameCIT-013
Drug Alias NameNeutrophil Extracellular Traps antagonist（Mediquest）CIT-013
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionNeutrophil Extracellular Traps inhibitorsAnti-Histone H4Anti-Histone H2A
TargetsNeutrophil Extracellular TrapsHistone H4Histone H2A
Therapy Area/IndicationsArthritis, RheumatoidHidradenitis Suppurativa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaPoland +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCitryll BV
China Registration ClassN/A

Develop Information

Active CompaniesCitryll BV
Inactive CompaniesN/A
Active IndicationsArthritis, RheumatoidHidradenitis Suppurativa
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A